RXi Pharmaceuticals Corporation (Nasdaq:RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that the Company''s President and Chief Executive Officer, Noah D. Beerman, will present a corporate overview at the 2010 BIO CEO & Investor Conference on Monday, February 8, 2010 at 11:30 a.m. ET.
Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual CEO & Investor Conference will take place February 8-9 at the Waldorf-Astoria in New York City.
A live webcast of the presentation will be available on the "Investors" section of the Company''s website, www.rxipharma.com. A replay of the presentation will be available for 30 days.
In addition, Mr. Beerman will participate in a therapeutic workshop panel entitled RNAi-Based Technologies: No Longer Single & Stranded. The one hour panel discussion will take place on February 8th at 3:00 and is open to conference registrants only. The panel discussion will not be audio or webcasted.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi has a comprehensive therapeutic platform that includes both RNAi compounds and delivery methods. RXi uses its own version of RNAi compounds -- rxRNA™ -- that provide an advanced alternative to conventional small interfering RNAs (siRNAs) and define the next generation of RNAi technology. rxRNA™ compounds are designed specifically for therapeutic use and contain many of the properties required to progress RNAi based drugs into the clinic. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is experienced in developing RNAi products; and a strong early intellectual property position in RNAi chemistry and delivery. www.rxipharma.com
ABOUT THE BIO CEO & INVESTOR CONFERENCE
Now in its twelfth year, the BIO CEO & Investor Conference 2010 is the largest investor conference focused on the biotechnology industry. The conference provides a forum for public and private equity investors, research analysts, investment bankers and senior-level industry executives to learn about and discuss investment trends and investment opportunities in the biotechnology industry. For more information, visit www.ceo.bio.org.
Contacts:
RXi Pharmaceuticals
Donna Falcetti, 508-929-3615
ir@rxipharma.com
or
Investors
S.
A. Noonan Communications
Susan Noonan, 212-966-3650
susan@sanoonan.com
or
Media
Rx
Communications Group
Eric Goldman, 917-322-2563
egoldman@rxir.com